The Death of Birth — Our Dismal Fertility Rates

Through Collapsed Fertility Rates, We Are Self-Exterminating

Recent Reports on Male Birth Control

This last week has seen a plethora of news about male birth control (MBC). A hormonal contraceptive, composed of testosterone and progestin — a synthetic form of progesterone, was reported in the Journal of Clinical Endocrinology & Metabolism. The pill, taken once a day, reportedly has a 98% efficacy, the same as female birth control pills. In addition, the effect is easily reversed.There is little certainty regarding possible side effects, due to a lack of long term studies. Early results, however, indicate that they may be minor (weight gain, for instance). An injectable form may be available in the US next year.Regarding its reliability, the article’s lead author, Peter Y. Liu, associate professor at the University of Sydney, states “The rate of suppression is comparable to that achieved after a vasectomy.”

It should be noted that these are not the results of new research. They are a meta-analysis of 30 previous studies having an aggregate sample of 1,756 men.

Progress in this field has been slow in part because drug companies believe that little profit can be earned by pursuing MBC research. The Royal Society of Chemistry reported last June that the German pharmaceutical titan, Bayer, cancelled its research and development program for the development of such contraception.

Despite the meager interest on the part of big Pharma, research into various methods of MBC continues. Questions regarding interest on the part of men have now been answered in a number of studies and non-scientific surveys. As reported here, “According to Dr. Bill Bremner, chair and director, respectively, of the University of Washington Department of Medicine and the Male Contraception Research Center, ‘up to 80 percent of men surveyed worldwide claimed they would use a new male contraceptive.’”

For an example of the of a survey, see this poll.

It appears that, despite meager interest on the part of large pharmaceutical corporations, interest on the part of both men and women in the development of MBC is anything but lacking.

Comments are closed.